Credit Suisse’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$8.2M Sell
201,642
-2,131
-1% -$79.9K 0.01% 1021
2023
Q4
$7.53M Sell
203,773
-3,574
-2% -$135K 0.01% 1094
2023
Q3
$7.92M Sell
207,347
-19,272
-9% -$789K 0.01% 1013
2023
Q2
$8.17M Buy
226,619
+48,436
+27% +$1.65M 0.01% 1026
2023
Q1
$6.8M Buy
178,183
+4,038
+2% +$189K 0.01% 1122
2022
Q4
$9.91M Buy
174,145
+3,684
+2% +$189K 0.01% 940
2022
Q3
$6.74M Buy
170,461
+4,682
+3% +$207K 0.01% 1102
2022
Q2
$7.29M Sell
165,779
-3,073
-2% -$133K 0.01% 1080
2022
Q1
$6.73M Buy
168,852
+813
+0.5% +$29K 0.01% 1260
2021
Q4
$6.76M Sell
168,039
-7,099
-4% -$265K ﹤0.01% 1787
2021
Q3
$7.13M Buy
175,138
+24,482
+16% +$1.02M ﹤0.01% 1778
2021
Q2
$6.84M Sell
150,656
-4,876
-3% -$216K ﹤0.01% 1829
2021
Q1
$6.48M Sell
155,532
-104,386
-40% -$4.77M ﹤0.01% 1861
2020
Q4
$11.1M Buy
259,918
+96,066
+59% +$3.45M 0.01% 1511
2020
Q3
$4.31M Sell
163,852
-63,178
-28% -$1.76M ﹤0.01% 1885
2020
Q2
$6.09M Buy
227,030
+129,379
+132% +$2.92M ﹤0.01% 1586
2020
Q1
$1.76M Sell
97,651
-80,336
-45% -$1.52M ﹤0.01% 2220
2019
Q4
$3.15M Buy
177,987
+29,824
+20% +$517K ﹤0.01% 2244
2019
Q3
$2.3M Sell
148,163
-78,335
-35% -$1.29M ﹤0.01% 2370
2019
Q2
$3.89M Buy
226,498
+23,625
+12% +$381K ﹤0.01% 1945
2019
Q1
$3.27M Buy
202,873
+46,208
+29% +$749K ﹤0.01% 2026
2018
Q4
$2.29M Buy
156,665
+60,375
+63% +$963K ﹤0.01% 2134
2018
Q3
$1.75M Sell
96,290
-14,539
-13% -$255K ﹤0.01% 2450
2018
Q2
$1.87M Sell
110,829
-40,296
-27% -$762K ﹤0.01% 2526
2018
Q1
$2.96M Buy
151,125
+27,353
+22% +$530K ﹤0.01% 2107
2017
Q4
$2.51M Sell
123,772
-151,686
-55% -$2.79M ﹤0.01% 2261
2017
Q3
$4.78M Buy
275,458
+28,945
+12% +$392K ﹤0.01% 1798
2017
Q2
$3.16M Sell
246,513
-14,861
-6% -$198K ﹤0.01% 1911
2017
Q1
$3.39M Buy
261,374
+128,861
+97% +$1.63M ﹤0.01% 1936
2016
Q4
$1.31M Sell
132,513
-380,408
-74% -$4.17M ﹤0.01% 2809
2016
Q3
$6.2M Buy
512,921
+7,269
+1% +$74.3K 0.01% 1497
2016
Q2
$4.36M Sell
505,652
-23,395
-4% -$231K ﹤0.01% 1730
2016
Q1
$5.01M Buy
529,047
+38,061
+8% +$358K 0.01% 1528
2015
Q4
$8.51M Sell
490,986
-69,948
-12% -$1.11M 0.01% 1254
2015
Q3
$7.53M Sell
560,934
-87,914
-14% -$1.77M 0.01% 1288
2015
Q2
$14.7M Buy
648,848
+78,418
+14% +$1.38M 0.01% 1010
2015
Q1
$8.15M Sell
570,430
-22,443
-4% -$324K 0.01% 1323
2014
Q4
$5.72M Buy
592,873
+71,572
+14% +$636K 0.01% 1659
2014
Q3
$4.74M Buy
521,301
+188,689
+57% +$1.8M ﹤0.01% 1790
2014
Q2
$3.29M Sell
332,612
-186,381
-36% -$1.58M ﹤0.01% 2315
2014
Q1
$6.59M Buy
518,993
+173,177
+50% +$2.57M 0.01% 1540
2013
Q4
$5.18M Buy
345,816
+2,670
+0.8% +$34.3K ﹤0.01% 1818
2013
Q3
$3.79M Buy
343,146
+173,514
+102% +$1.45M ﹤0.01% 1868
2013
Q2
$1.35M Buy
+169,632
New +$1.08M ﹤0.01% 2565

Other funds holding HALO

Credit Suisse's HALO Position: Q1 2024 in Review

Credit Suisse reduced its Halozyme (HALO) stake by 1% in Q1 2024, selling an estimated $79.9K and leaving 201,642 shares worth $8.2M. The position accounts for 0.01% of the portfolio, ranked #1021.

Credit Suisse first reported a position in HALO in Q2 2013 and has held it in 44 quarters since. The position peaked at $14.7M in Q2 2015. 414 funds tracked by Wall St. Rank hold HALO as of Q1 2024.

  • Credit Suisse held 201,642 shares of Halozyme worth $8.2M as of Q1 2024.
  • Credit Suisse sold 2,131 Halozyme shares in Q1 2024, an estimated $79.9K.
  • Halozyme made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #1021 holding.
  • Credit Suisse first reported a position in Halozyme in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Halozyme position peaked at $14.7M in Q2 2015.
  • 414 funds tracked by Wall St. Rank held Halozyme as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.